CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today announced that it has selected the first development candidate from its Targeted Cancer Drug Development Platform. Curis is seeking to use this platform to discover and develop a portfolio of small molecule multi-target inhibitors against a wide range of cancer types. For each drug program, compounds are being designed by covalently linking two active drug components, or pharmacophores. Each pharmacophore targets at least one distinct clinically validated cancer target, where Target A remains constant throughout all programs currently under development at Curis, and Target B is a different clinically validated or promising cancer target that varies between programs. Specific Target A-Target B pharmacophore combinations define each of the several drug programs that are currently under development. Curis has filed several patent applications covering its multi-target inhibitor programs.
